Evidence map›Paper›PMID 42365008›Full record

Trial reportBlood cancer journal2026

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Elias Jabbour, Caitlin R Rausch, Hannah Goulart, Nitin Jain, Farhad Ravandi, Abhishek Maiti, Yesid Alvarado, Jan Burger, Musa Yilmaz, Issa Khouri and 8 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elias JabbourDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. ejabbour@mdanderson.org.ORCID http://orcid.org/0000-0003-4465-6119
Caitlin R RauschDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4166-5717
Hannah GoulartDepartment of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1945-2571
Nitin JainDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Farhad RavandiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7621-377X
Abhishek MaitiDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9043-538X
Yesid AlvaradoDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1652-7937
Jan BurgerDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6177-7572
Musa YilmazDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4498-4895
Issa KhouriDepartment of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Partow KebriaeiDepartment of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey JorgensenDepartment of Hematopathology and Molecular Diagnostics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1875-2986
Sa A WangDepartment of Hematopathology and Molecular Diagnostics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9385-9911
Xuemei WangDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ejiroghene MayorDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca S GarrisDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicholas J ShortDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2983-2738
Hagop KantarjianDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1908-3307

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672U.S. Department of Health & Human Services | National Institutes of Health (NIH) CA016672
6 · The paper itself

Abstract

Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL). This phase 2 single-center study evaluated inotuzumab 0.6 mg/m

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalInotuzumab OzogamicinNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaAdultAgedFemaleHumansMaleMiddle AgedRemission InductionYoung AdultAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalInotuzumab Ozogamicin

Identifiers

PMID42365008
PMCPMC13572437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.